Opportunities and challenges following approval of resmetirom for MASH liver disease

Nat Med. 2024 Apr 19. doi: 10.1038/s41591-024-02958-z. Online ahead of print.

Jeffrey V Lazarus^{1

2

3

4}, Dana Ivancovsky Wajcman^{5

6}, Henry E Mark^{5

6}, Zobair M Younossi^{6

7}, Christopher J Kopka⁵, Nevin Cohen⁸, Meena B Bansal⁹, Michael Betel¹⁰, Paul N Brennan^{6

11}

¹ City University of New York Graduate School of Public Health and Health Policy (CUNY SPH), New York, NY, USA. Jeffrey.Lazarus@sph.cuny.edu.
² Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona, Barcelona, Spain. Jeffrey.Lazarus@sph.cuny.edu.
³ Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain. Jeffrey.Lazarus@sph.cuny.edu.
⁴ Global NASH Council, Washington, DC, USA. Jeffrey.Lazarus@sph.cuny.edu.
⁵ Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona, Barcelona, Spain.
⁶ Global NASH Council, Washington, DC, USA.
⁷ Beatty Liver and Obesity Research Program, Inova Health System, Falls Church, VA, USA.
⁸ City University of New York Graduate School of Public Health and Health Policy (CUNY SPH), New York, NY, USA.
⁹ Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
¹⁰ Fatty Liver Alliance, Toronto, Ontario, Canada.
¹¹ Division of Molecular and Clinical Medicine, University of Dundee, Dundee, UK.

No abstract available